CriticalAntiepileptics. Carboxamide derivatives×Pharmacokinetic enhancer (booster) for antiretroviral therapy
Updated · Methodology
Mechanism
Carbamazepine is a strong inducer of CYP3A4: it speeds up the metabolism of drugs cleared by this enzyme and can lower their levels (carbamazepine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). CYP3A also metabolises cobicistat itself. In a study with elvitegravir and cobicistat, carbamazepine 200 mg twice daily lowered the area under the concentration-time curve (AUC) of cobicistat by 84% and its trough level by 90% (cobicistat SmPC, European Medicines Agency, EMA). Levels of atazanavir or darunavir, the drugs that cobicistat boosts, fall as well, so treatment of human immunodeficiency virus (HIV) infection may stop working and the virus may become resistant (cobicistat SmPC, EMA). In the other direction, cobicistat inhibits CYP3A. In the same study, the AUC of carbamazepine rose by 43%, while the AUC of its active metabolite, carbamazepine-10,11-epoxide, fell by 35% (cobicistat SmPC, EMA, and carbamazepine SmPC, AEMPS).
Symptoms
The main risk is that treatment of human immunodeficiency virus (HIV) infection stops working and the virus becomes resistant (cobicistat summary of product characteristics, SmPC, European Medicines Agency, EMA). Loss of treatment effect causes no symptoms by itself and is detected by virological testing (cobicistat label, US Food and Drug Administration, FDA). Higher carbamazepine levels may cause dizziness, drowsiness, poor coordination (ataxia) and double vision (carbamazepine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).
Management
The combination is contraindicated. Carbamazepine is on the cobicistat contraindication list together with phenobarbital and phenytoin. As strong CYP3A inducers, they lower the levels of cobicistat and of the drug it boosts, and treatment may lose its effect (cobicistat summary of product characteristics, SmPC, European Medicines Agency, EMA, and cobicistat label, US Food and Drug Administration, FDA). The same contraindication appears in the SmPCs of the combination tablets with cobicistat: darunavir/cobicistat, atazanavir/cobicistat and elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (SmPCs of these products, EMA). For a person taking cobicistat, choose seizure treatment without carbamazepine, phenobarbital or phenytoin (cobicistat SmPC, EMA, and FDA label). Oxcarbazepine and eslicarbazepine also induce CYP3A but are not contraindicated. With them, consider an alternative anticonvulsant or antiretroviral drug. If the combination is necessary, monitor for loss of virologic response (cobicistat FDA label). Before starting cobicistat and during treatment, consider possible interactions, review all concomitant medicines and monitor for their adverse effects (cobicistat FDA label). Carbamazepine can also lower the levels of human immunodeficiency virus (HIV) protease inhibitors and weaken or even cancel their effect (carbamazepine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). If carbamazepine and cobicistat have nevertheless been taken together, adjust the carbamazepine dose and/or monitor its blood levels, as with any CYP3A4 inhibitor (carbamazepine SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Carbamazepina, Tegretol 200 mg (nº registro 39955), sección 4.5 (2026)– AEMPS, CIMA, nº registro 39955, revisión 09/2026, secciones 4.3 y 4.5
- FDA: Tegretol (carbamazepine) prescribing information (2026)– FDA label, DailyMed setid 8d409411-aa9f-4f3a-a52c-fbcb0c3ec053, version 39, revised 08/2026, Contraindications and PRECAUTIONS: Drug Interactions
- EMA: Ficha técnica: Cobicistat (EU/1/13/872), sección 4.5 (2026)– EMA, Tybost 150 mg (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 113872001, consultada 10/2026, secciones 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Atazanavir/cobicistat, Evotaz (EU/1/15/1025), sección 4.3 (2026)– EMA, Evotaz 300 mg/150 mg comprimidos (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151025001, consultada 10/2026, sin fecha de revisión en CIMA, secciones 4.3 y 4.5
- EMA: Ficha técnica: Darunavir/cobicistat (EU/1/14/967), sección 4.3 (2026)– EMA, Rezolsta 800 mg/150 mg (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 114967001, consultada 10/2026, sección 4.3
- FDA: TYBOST (cobicistat) prescribing information (2026)– FDA, DailyMed setid 3784c35c-e87f-410c-900b-8fd6313c6010 (Gilead Sciences), versión 16 (SPL 10.02.2026, publicada 18.02.2026), secciones 4, 5.3, 7.1 y 7.3 (Table 7)
- EMA: Ficha técnica: Cobicistat, Tybost (EU/1/13/872), sección 4.3 (2026)– EMA, Tybost 150 mg comprimidos recubiertos con película (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 113872001, consultada 20.10.2026, sin fecha de revisión en CIMA, secciones 4.2, 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Elvitegravir/cobicistat/emtricitabina/tenofovir alafenamida, Genvoya (EU/1/15/1061), sección 4.3 (2026)– EMA, Genvoya 150 mg/150 mg/200 mg/10 mg comprimidos recubiertos con película (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151061001, consultada 20.10.2026, sin fecha de revisión en CIMA, secciones 4.3 y 4.5